Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

Annals of the Rheumatic Diseases

Volumn 75, Issue 2, 2016, Pages 382-389

  Seror, Raphaèle ^a,b,ad   Bootsma, Hendrika ^c   Saraux, Alain ^d   Bowman, Simon J ^e   Theander, Elke ^f   Brun, Johan G ^g   Baron, Gabriel ^a,b   Le Guern, Véronique ^h   Devauchelle Pensec, Valérie ^d   Ramos Casals, Manel ⁱ   Valim, Valeria ^j   Dörner, Thomas ^k   Tzioufas, Athanasios ^l   Gottenberg, Jacques Eric ^m   Laqué, Roser Solans ⁿ   Mandl, Thomas ^f   Hachulla, Eric ^o   Sivils, Kathy L ^p   Ng, Wan Fai ^q   Fauchais, Anne Laure ^r   Bombardieri, Stefano ^s   Priori, Roberta ^t   Bartoloni, Elena ^u   Goeb, Vincent ^v   Praprotnik, Sonja ^w   Sumida, Takayuki ^x   Nishiyama, Sumusu ^y   Caporali, Roberto ^z   Kruize, Aike A ^aa   Vollenweider, Cristina ^ab   Ravaud, Philippe ^a,b   Meiners, Petra ^c   Brito Zerón, Pilar ⁱ   Vitali, Claudio ^ac   Mariette, Xavier ^a   Gerli, Roberto ^u   Kallenberg, Cees ^c   De Vita, Salvatore ^ae   Demoulins, Frederic ^ad   Montecucco, Carlomaurizio ^z   Tomsic, Matija ^w   Scofield, Hal ^p   Valesini, Guido ^t   more..

^a INSERM   (France)

^b HÔTEL DIEU   (France)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^h Institut Cochin   (France)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^m UNIVERSITY HOSPITAL OF STRASBOURG   (France)

ⁿ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^o UNIV LILLE   (France)

^p OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^q NEWCASTLE UNIVERSITY   (United Kingdom)

^r LIMOGES UNIVERSITY HOSPITAL   (France)

^s UNIVERSITY OF PISA   (Italy)

^t SAPIENZA UNIVERSITY OF ROME   (Italy)

^u UNIVERSITY OF PERUGIA   (Italy)

^v AMIENS UNIVERSITY HOSPITAL   (France)

^w UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^x UNIVERSITY OF TSUKUBA   (Japan)

^y University of Tokyo   (Japan)

^z UNIVERSITY OF PAVIA   (Italy)

^aa UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^ab HOSPITAL ALEMÁN   (Argentina)

^ac Instituto San Giuseppe   (Italy)

^ad BICÊTRE HOSPITAL   (France)

^ae UNIVERSITY HOSPITAL OF UDINE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; HYDROXYCHLOROQUINE; METHOTREXATE; RITUXIMAB;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE COURSE; DISEASE DURATION; EUROPEAN LEAGUE AGAINST RHEUMATISM SJOGREN SYNDROME DISEASE ACTIVITY INDEX; EUROPEAN LEAGUE AGAINST RHEUMATISM SJOGREN SYNDROME PATIENT REPORTED INDEX; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METHODOLOGY; MINIMAL CLINICALLY IMPORTANT IMPROVEMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SJOEGREN SYNDROME; SYMPTOM; TREATMENT OUTCOME; MIDDLE AGED; PROCEDURES; PSYCHOLOGY; SELF EVALUATION; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; SYMPTOM ASSESSMENT;

AGED; DIAGNOSTIC SELF EVALUATION; DISEASE PROGRESSION; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; SYMPTOM ASSESSMENT;

EID: 84954398507     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206008     Document Type: Article

References (35)

1. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010;69:1103-9.
2. Seror R, Ravaud P, Mariette X, et al. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis 2011;70:968-72.
3. Seror R, Theander E, Brun JG, et al. Validation of EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2014.
4. Seror R, Mariette X, Bowman S, et al. Accurate detection of changes in disease activity in primary Sjogren's syndrome by the European League Against Rheumatism Sjogren's Syndrome Disease Activity Index. Arthritis Care Res (Hoboken) 2010;62:551-8.
5. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
6. Gottenberg JE, Seror R, Miceli-Richard C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS ONE 2013;8:e59868.
7. Seror R, Gottenberg JE, Devauchelle-Pensec V, et al. European league against rheumatism Sjogren's syndrome disease activity index and European league against rheumatism Sjogren's syndrome patient-reported index: a complete picture of primary Sjogren's syndrome patients. Arthritis Care Res (Hoboken) 2013;65:1358-64.
8. Wells GA, Boers M, Shea B, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32:2016-24.
9. Wells G, Boers M, Tugwell P. Low disease activity state in rheumatoid arthritis: concepts and derivation of minimal disease activity. Clin Exp Rheumatol 2006;24: S52-9.
10. Hahn GJ, Meeker WQ. Statistical intervals: a guide for practitioners. New York: John Wiley & Sons, 1991.
11. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004;50:1270-6.
12. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann Intern Med 2014;160:233-42.
13. Gottenberg JE, Ravaud P, Puechal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial. JAMA 2014;312:249-58.
14. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
15. Meiners PM, Vissink A, Kroese FG, et al. Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis 2014;73:1393-6.
16. Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2015;74:526-31.
17. Shapiro DE. The interpretation of diagnostic tests. Stat Methods Med Res 1999;8:113-34.
18. Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52:2625-36.
19. Gladman DD, Urowitz MB, Kagal A, et al. Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol 2000;27:377-9.
20. Petri M, Genovese M, Engle E, et al. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991;34:937-44.
21. Beaton DE, Bombardier C, Katz JN, et al. Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important Difference. J Rheumatol 2001;28:400-5.
22. Tubach F, Wells GA, Ravaud P, et al. Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues. J Rheumatol 2005;32:2025-9.
23. Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis 2005;64:34-7.
24. Pham T, Tubach F. Patient acceptable symptomatic state (PASS). Joint Bone Spine 2009;76:321-3.
25. Gottenberg J-E, Ravaud P, Puéchal X, et al. Inefficacy of hydroxychoroquine in primary Sjögren's syndrome: results of the JOQUER trial. Arthritis Rheum 2012;64.
26. Ramos-Casals M, Brito-Zeron P, Solans R, et al. Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford) 2014;53:321-31.
27. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004;50:2240-5.
28. Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren's syndrome treated with rituximab. Ann Rheum Dis 2012;71:1297-302.
29. Moerman RV, Arends S, Meiners PM, et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis 2014;73:472-4.
30. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Tolerance and efficacy of Rituximab in primary Sjögren's syndrome (TEARS): results of a randomized controlled trial. Ann Rheum Dis 2012;71:75.
31. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343-9.
32. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
33. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
34. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
35. Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the Auto Immune and Rituximab registry. Ann Rheum Dis 2013;72: 1026-31.